BioLamina AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BioLamina AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014284
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioLamina AB (BioLamina) is a biotechnology company that focuses on the development, manufacture and distribution of cell culture reagents intended for culturing primary cells. The company offers a wide portfolio of chemically defined and xeno-free laminin proteins. Its product portfolio includes Laminin-521, a recombinant human protein, which is the natural laminin for pluripotent stem cells; Laminin-111, for early epithelial development and differentiation of the epiblast; and LAMscreen that enables the screening of the best laminins for different cell types. BioLamina’s products find application in maintaining endothelial cells, eye applications, hepatic, kidney cell culture, neural, pancreatic and skeletal muscle applications. The company operates through its distribution partners in Asia, Europe and the Americas, among others. BioLamina is headquartered in Stockholm, Sweden.

BioLamina AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BioLamina AB, Medical Devices Deals, 2011 to YTD 2017 8
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
BioLamina AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 10
Licensing Agreements 11
BioLamina Enters into Licensing Agreement with Cevec Pharma 11
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 12
Acquisition 13
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 13
BioLamina AB – Key Competitors 14
BioLamina AB – Key Employees 15
BioLamina AB – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
BioLamina AB, Pharmaceuticals & Healthcare, Key Facts 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
BioLamina AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
BioLamina AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
BioLamina AB, Medical Devices Deals, 2011 to YTD 2017 8
BioLamina AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 10
BioLamina Enters into Licensing Agreement with Cevec Pharma 11
BioLamina Enters Into Licensing Agreement With Vitrolife For Cryopreservation Medium 12
Vitrolife Acquires 4.6% Stake In Biolamina For US$0.6 Million 13
BioLamina AB, Key Competitors 14
BioLamina AB, Key Employees 15
BioLamina AB, Subsidiaries 16

★海外企業調査レポート[BioLamina AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Brunei LNG Sdn Bhd:企業の戦略的SWOT分析
    Brunei LNG Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Kone Corporation:企業の戦略・SWOT・財務分析
    Kone Corporation - Strategy, SWOT and Corporate Finance Report Summary Kone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company's marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple m …
  • A. K. Capital Services Ltd (530499):企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Network Rail Ltd:企業の戦略的SWOT分析
    Network Rail Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Grand Gulf Energy Ltd (GGE):石油・ガス:M&Aディール及び事業提携情報
    Summary Grand Gulf Energy Ltd (Grand Gulf Energy), formerly Alto Energy International Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in the US oil and gas basins. It holds interests in Napoleonville Salt Dome pro …
  • Shanghai Pharmaceutical Co Ltd (601607):医療機器:M&Aディール及び事業提携情報
    Summary Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. The company carries out the research and development, manufacture and sale of pharmaceutical products for treating HER2 positive advanced breast cancer, systemic a …
  • Cloverdale Paint Inc:企業の戦略的SWOT分析
    Cloverdale Paint Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Henkel AG & Co. KGaA:企業のM&A・事業提携・投資動向
    Henkel AG & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Henkel AG & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Sociedad General de Aguas de Barcelona SA:企業の戦略的SWOT分析
    Sociedad General de Aguas de Barcelona SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • KfW Group:企業の戦略・SWOT・財務分析
    KfW Group - Strategy, SWOT and Corporate Finance Report Summary KfW Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • iMedX Inc-医療機器分野:企業M&A・提携分析
    Summary iMedX Inc (iMedX) is a provider of medical document management and health information solutions. The company offers transcription services and coding services. It provides iMedX Express web based platforms and iMedX Mobile with DocAssist applications. iMedX’s transcription services comprise …
  • Odonate Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Odonate Therapeutics LLC (Odonate) is a company that develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate’s lead product candidate, tesetaxel, is a novel orally administered taxane use …
  • Peptimimesis SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Peptimimesis SAS (Peptimimesis) is a biopharmaceutical company that discovers and develops transmembrane therapeutic peptides. The company’s proprietary platform delivers a set of drug candidates that act on strategic targets in the field of immuno-oncology, oncology and immune diseases. Its …
  • Cancer Genetics Inc (CGIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that provides diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic info …
  • Bracket Global LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Bracket Global LLC (Bracket Global) is a clinical research organization that provides clinical technology solution that helps to improve clinical research experience. The organization’s Bracket eCOA is a flexible platform for electronic Clinical Outcomes Assessments that collects data from p …
  • Genocea Biosciences Inc (GNCA):企業の財務・戦略的SWOT分析
    Summary Genocea Biosciences Inc (Genocea), formerly Genocea Inc, is a cancer vaccines provider. The company discovers and develops T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. It provides Gen-009 and Gen-010 neoantigen cancer Vaccine pipeline.Genoceaatlas tec …
  • Juniper Networks, Inc.:企業の戦略・SWOT・財務情報
    Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Range Resources Corp (RRC):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Corp (Range) is independent oil, natural gas and natural gas liquids (NGL) company that explores, develops, and acquires natural gas and oil properties in the US. It has oil and gas properties in the Appalachian basin and Northern Louisiana of the US. Range’s natural gas and …
  • The Lion Group:企業の戦略・SWOT・財務情報
    The Lion Group - Strategy, SWOT and Corporate Finance Report Summary The Lion Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆